Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 1 to 20 of 312

1.

Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ.

J Urol. 2011 Mar;185(3):869-75. doi: 10.1016/j.juro.2010.10.057. Epub 2011 Jan 15.

2.

The significance and management of transitional cell carcinoma of the prostate.

Montie JE, Wood DP Jr, Mendendorp SV, Levin HS, Pontes JE.

Semin Urol. 1990 Nov;8(4):262-8. No abstract available.

PMID:
2284532
3.

The risk of radical cystectomy.

Montie JE, Wood DP Jr.

Br J Urol. 1989 May;63(5):483-6.

PMID:
2731007
4.

Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective study.

Wood DP Jr, Montie JE, Pontes JE, Levin HS.

J Urol. 1989 Jul;142(1):83-5.

PMID:
2733111
5.

Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer.

Montie JE, Wood DP Jr, Pontes JE, Boyett JM, Levin HS.

Cancer. 1989 Jan 15;63(2):381-5.

6.

Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer.

Wood DP Jr, Montie JE, Pontes JE, VanderBrug Medendorp S, Levin HS.

J Urol. 1989 Feb;141(2):346-9.

PMID:
2913357
7.

Retained straight catheter: complication of clean intermittent catheterization.

Klein EA, Wood DP, Kay R.

J Urol. 1986 Apr;135(4):780-1.

PMID:
3959201
9.

The molecular staging of prostate cancer.

Wood DP Jr.

Semin Urol. 1995 May;13(2):96-102. Review. No abstract available.

PMID:
7638475
10.
11.

Salvage radical prostatectomy in the management of locally recurrent prostate cancer after 125I implantation.

Brenner PC, Russo P, Wood DP, Morse MJ, Donat SM, Fair WR.

Br J Urol. 1995 Jan;75(1):44-7.

PMID:
7850294
12.

Metallothionein gene expression in bladder cancer exposed to cisplatin.

Wood DP Jr, Klein E, Fair WR, Chaganti RS.

Mod Pathol. 1993 Jan;6(1):33-5.

PMID:
8426855
13.

Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level.

Forman JD, Meetze K, Pontes E, Wood DP Jr, Shamsa F, Rana T, Porter AT.

J Urol. 1997 Oct;158(4):1436-9; discussion 1439-40.

PMID:
9302138
15.

Prognostic implications of a positive apical margin in radical prostatectomy specimens.

Fesseha T, Sakr W, Grignon D, Banerjee M, Wood DP Jr, Pontes JE.

J Urol. 1997 Dec;158(6):2176-9.

PMID:
9366338
17.

Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy.

Garg MK, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood DP Jr, Porter AT, Forman JD.

Urology. 1998 Jun;51(6):998-1002.

PMID:
9609639
18.

Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer.

Gheiler EL, Tefilli MV, Tiguert R, Grignon D, Cher ML, Sakr W, Pontes JE, Wood DP Jr.

Urology. 1998 May;51(5):789-95.

PMID:
9610593
19.

Salvage surgery or salvage radiotherapy for locally recurrent prostate cancer.

Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Forman J, Pontes JE, Wood DP Jr.

Urology. 1998 Aug;52(2):224-9.

PMID:
9697786
20.

Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer.

Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon DJ, Pontes JE, Wood DP Jr.

J Urol. 1998 Sep;160(3 Pt 1):802-6.

PMID:
9720552

Supplemental Content

Support Center